GREY:ATBPF - Post by User
Comment by
MrMugsyon Dec 11, 2020 1:40pm
161 Views
Post# 32089462
RE:RE:RE:Long term
RE:RE:RE:Long termRyeman40 wrote: All the good points i got from interview
13:30 Dan says if you solve problem with nsaid safety the drug is worth 30billion lifetime
20:00 Dr. Stauffer was actually involved in developing opioids
21:15 Their "unknown university" has one of the best chemists in H2S and working on different indications and fresh ip's
32:40 After foray into US institutional investors meetings first part of winter look into uplist
38:00 Lol Dan's comment on being public ceo and watching what he has to say but their safety was 1500% better. Superb results.
38:50 Dr. Stauffer bought on open market. Put his money where his mouth is lol.
42:30 Dr. Stauffer expects 150 mg to hit statistical significant efficacy when powered to do so in trial.
58:50 Filing IND after Christmas and also another study underway called absorption, metabolism, and excretion which will be longer than 2 weeks. More data under their belt going forward and also metion 90% of americans take NSAID.
1:01:40 About another 60million for duration of trials either dilution or partner.
1:06:30 Already thinking about other indications like cardiology and alzheimer's. Revolves around inflammation.
1:12:00 This one is big in my books but they have a good relationship with fda (thanks Joe!) and they had very good advice from them that they took and it worked in their favor.
1:24:00 Engineer another drug from their chemist at said university for rare diseases.
Once first drug is approved and i think it's almost guaranteed since efficacy will be there and most of it will hinge on the safety aspect, this will be nothing but a cash cow with future indications
This really is what you look for when buying into biotech. Safety second to none. Efficacy the same or better. And future ip's as far as you can see.
Most traders won't like this because i don't think price will appreciate for awhile (but who knows with markets these days) but investors love this because they see value well into the future especially being so undervalued at the moment.
Right-o Ryman.
I think the price will appreciate though.
Just finished a long thought on CEO but will say this here ...
I expect that JP Morgan will bring some excitement after January 11-14 and we should see the comprehensive corporate update a day or two earlier than that - guessing. Hoping that gets all these new investors and institutional buyers ramping up their purchases and our longer investors will also get greedy and want to join the buying train. All the while, management will be ready to push the button on a US exchange as the share price rises. Many wild cards to help in the share price appreciation. It all depends how exciting ATE can make the future sound. Before you know it, they're heading into new drug app and FDA meeting and we're starting Phase 3. Excitement fills the air and the price is smoking. Real or not real ? I can't really say.